Skip to main content

Biomarker-Directed Stratification, Evolving Therapies and Clinical Trials for

Relapsed/Refractory Nodal TFH Cell Lymphoma

The Current and Evolving Role and Guidelines for the Dual Delta-Gamma P/3K Inhibitor Duvelisib

FEATURED AUTHORITIES ON PERIPHERAL T-CELL LYMPHOMA
Click on Speaker to View Their iQ&A Sessions

Steven Horwitz, MD

Steven Horwitz, MD

Associate Attending, Department of Medicine

Memorial Sloan Kettering Cancer Center

New York, NY

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil

Associate Professor of Haematology

Oxford University and Lead of the Haematology and Lymphoma Service

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom

Neha Mehta-Shah, MD

Neha Mehta-Shah, MD

Associate Professor of Medicine, Division of Oncology

Siteman Cancer Center

WashU Medicine

Washington University

St. Louis, MO

Christina Poh, MD

Christina Poh, MD

Physician, Fred Hutch Cancer Center

Assistant Professor, Division of Hematology and Oncology

University of Washington School of Medicine

Seattle, WA

ACCESS RESOURCES AND TRIALS
IN PTCL THERAPY

ABOUT THIS PROGRAM AND FACULTY DISCLOSURES

Latest Videos |view all videos

Based on the PRIMO Phase 2 study evaluating duvelisib in PTCL-TFH, how should oncologists managing patients with this variant of PTCL-TFH think about deploying this dual gamma-delta PI3K inhibitor in the R/R subgroup afflicted with this PTCL subtype?

Based on the PRIMO Phase 2 study evaluating duvelisib in PTCL-TFH, how should oncologists managing patients with this variant of PTCL-TFH think about deploying this dual gamma-delta PI3K inhibitor in the R/R subgroup afflicted with this PTCL subtype?

Can you discuss what the current post-CHOP therapy landscape looks like for persons with PTCL-TFH, in particular for patients who have relapsed, failed, and/or are resistant to CHOP?

Can you discuss what the current post-CHOP therapy landscape looks like for persons with PTCL-TFH, in particular for patients who have relapsed, failed, and/or are resistant to CHOP?

Can you take us through your diagnostic protocols, biomarker panels, and pathway approaches to establish the presence of PTCL-TFH; and, your considerations in those patients who have relapsed/resistant PTCL-TFH?

Can you take us through your diagnostic protocols, biomarker panels, and pathway approaches to establish the presence of PTCL-TFH; and, your considerations in those patients who have relapsed/resistant PTCL-TFH?

At what point with PTCL-TFH do you introduce duvelisib treatment? Do you use it in the first-line setting or do you currently reserve it for R/R patients and as a bridge for allograft stem cell transplantion?

At what point with PTCL-TFH do you introduce duvelisib treatment? Do you use it in the first-line setting or do you currently reserve it for R/R patients and as a bridge for allograft stem cell transplantion?

Can you discuss the challenges of classifying subtypes of PTCL—especially PTCL-TFH—and how to optimize biomarker-based diagnosis of this condition to ensure actionable and precision-based therapies are identified?

Can you discuss the challenges of classifying subtypes of PTCL—especially PTCL-TFH—and how to optimize biomarker-based diagnosis of this condition to ensure actionable and precision-based therapies are identified?

In light of the evidence for duvelisib in R/R PTCL-TFH as well as its use for bridging to allograft bone transplantation, what can specialists draw on to guide their use of duvelisib-centric regiments in R/R patients?

In light of the evidence for duvelisib in R/R PTCL-TFH as well as its use for bridging to allograft bone transplantation, what can specialists draw on to guide their use of duvelisib-centric regiments in R/R patients?

Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant?

Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant?

Professor Horwitz, can you please give us a general introduction to the subtype-specific landscape of PTCL, with a focus on nodal PTCL-TFH—T follicular helper phenotype?

Professor Horwitz, can you please give us a general introduction to the subtype-specific landscape of PTCL, with a focus on nodal PTCL-TFH—T follicular helper phenotype?

Can you discuss what we learned from the PRIMO trial that focused on the efficacy, actionable outcome signals observed with duvelisib in this trial, and the safety of the dual delta-gamma PI3K inhibitor, duvelisib?

Can you discuss what we learned from the PRIMO trial that focused on the efficacy, actionable outcome signals observed with duvelisib in this trial, and the safety of the dual delta-gamma PI3K inhibitor, duvelisib?